Transforming Mind Solutions

Five Fibre score: 60/100. Assess 11/20, Build 10/20, Launch 18/20, Grow 6/20, Amplify 14.5/20.

Assessment band: Growth Gaps.

Transforming Mind Solutions has an identifiable clinical business, specialist leadership and an active franchise proposition. The most consequential finding is that public operating claims need to be read alongside a recent regulator assessment. A healthcare franchise requires commercial viability and dependable service delivery together. Training descriptions, a published clinic directory and international announcements do not independently prove either. This review recognises the support structure while qualifying the areas where current public evidence is incomplete or contradictory.

The Northampton service’s CQC report was published on 27 April 2026 following assessment on 26 January. It rated the service Requires improvement overall, with Safe and Well-led at that level and Effective, Caring and Responsive rated Good. The report identifies training, competence, policy and governance weaknesses and requests corrective action. These findings concern the assessed service and scope, not every franchise or treatment across the network. No later published reassessment was located during this review, which does not establish that no improvements have since been made.

The regulator also records positive patient feedback and areas of good practice. Its detailed governance section describes an action plan but questions the clarity of ownership and deadlines. That combination matters: the appropriate priority is to establish what has been corrected and verified, rather than ignore the findings or assume all operations are unsafe. Build receives partial credit for described resources and training, with the independent findings preventing an unqualified conclusion that the supporting systems are fully established. This is a franchise-foundation assessment, not a clinical treatment recommendation.

Ownership and geography also need reconciliation. The public directory mixes UK places with Dublin and Lagos, and some labels for other international destinations link to UK pages. A city list is therefore not a verified franchise-owner count. Lagos is explicitly described as a franchise opened in October 2025 with a named local clinical team and practitioner training. It demonstrates transfer beyond the central founders, but must not be added to UK franchise totals. Satellite arrangements, central clinics and independently owned franchises should remain separate categories.

The public team page distinguishes Richard Williams as founder and CEO, Professor Alex O’Neill-Kerr as medical director, and Carole Cook as operations manager responsible for systems and franchise administration. Other brand materials use founding descriptions differently. Named operational support is useful evidence, but it does not prove a UK clinic can operate successfully without daily founder input. The recruitment site’s continued emphasis on central leadership makes documented delegation, clinical cover and operational accountability especially important as locations expand.

Commercial evidence is less developed publicly than the service proposition. The dedicated recruitment site says detailed costs are supplied on enquiry and offers no representative owner accounts or quantified return model. A new clinic and an existing practice adding a service will have different equipment, staffing, premises and working-capital requirements. Patient numbers, market forecasts and positive testimonials are not substitutes for a locally costed business plan. This review does not repeat broad treatment-approval or market-size claims as independently verified evidence of investment quality.

Launch has a practical registration route offering a prospectus, discovery call and territory outline. The complete selection and approval sequence is less public. Grow also lacks monthly enquiry, attribution and conversion data; an overseas opening is an outcome rather than a measured UK recruitment engine. Amplify benefits from local pages, central campaigns and referral routes, but public material does not demonstrate clinic-level commercial reporting or a continuing local plan matched to suitable clinical capacity. Private systems, patient records, training assessments and live referrals were not tested.

The connected priority is to verify governance improvement and sustainable local delivery before accelerating recruitment. A stronger enquiry pipeline cannot compensate for unresolved accountability or an unclear clinic financial model. Equally, identified public-evidence limits should guide specific questions rather than be presented as proof that every private capability is absent.

Assess priority: obtain a complete current investment and representative clinic economics. Reconcile UK ownership, satellite arrangements and overseas franchises, with clear leadership responsibilities.

Build priority: verify corrective actions from the Northampton assessment, supported by evidence of completion. Control procedures, training competence, accountability and cover before copying the model into further clinics.

Launch priority: clarify the full clinical, commercial and suitability discovery process. Explain costs and responsibilities for both new and existing-practice formats before commitment.

Grow priority: measure UK candidate sources, qualification and conversion. Prioritise territories according to verified support capacity and viable local delivery.

Amplify priority: reconcile each clinic’s online journey and referral handover. Connect suitable enquiries with assessed capacity, appropriate follow-up and clinic-level commercial measurement.